Stryker Corporation $SYK Stock Holdings Lessened by Peachtree Investment Partners LLC

Peachtree Investment Partners LLC reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 39.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,692 shares of the medical technology company’s stock after selling 1,752 shares during the quarter. Peachtree Investment Partners LLC’s holdings in Stryker were worth $847,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. purchased a new stake in Stryker in the 4th quarter worth approximately $26,000. Sankala Group LLC acquired a new stake in shares of Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker during the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. purchased a new position in shares of Stryker during the 4th quarter valued at $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker in the fourth quarter worth $28,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on SYK shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. UBS Group began coverage on Stryker in a research report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 target price on the stock. Barclays reduced their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Finally, Truist Financial boosted their price target on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $386.28.

Stryker Stock Down 0.1%

Stryker stock opened at $338.80 on Monday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The firm’s fifty day simple moving average is $324.61 and its 200-day simple moving average is $333.40. The company has a market capitalization of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.